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The present study investigated the insulin sensitivity, hypoglycemic, and hypolipidemic activities of ethanolic extract of Mirabilis
jalapa L. root (EEM) in normal and diabetic mice. After induction of diabetes with streptozotocin, both normal and diabetic mice
were singly or repeatedly for 28 days administrated with EEM at doses of 2, 4, 8g/kg, respectively. Before induction of diabetes,
mice were administrated with EEM at doses of 2, 4, 8g/kg for 14 days and were injected with streptozotocin and continued on
EEM administration for another 28 days. Both after and before induction of diabetes, repeated administration with 4, 8g/kg EEM
continually lowered blood glucose level, decreased serum insulin level and improved insulin sensitivity index, and lowered serum
total cholesterol, triglyceride levels and triglyceride content in liver and skeletal muscle, and increased glycogen content in these
tissues; but repeated administration had no inﬂuence on those indexes of normal mice. Single administration with EEM (4, 8g/kg)
showed hypoglycemic eﬀect in oral glucose tolerance test in normal and diabetic mice. Single administration with EEM had no
hypoglycemic and hypolipidemic eﬀects on normal and diabetic mice. These results suggest that EEM possesses both potential
insulin sensitivity, hypoglycemic, and hypolipidemic eﬀects on diabetes.
1.Introduction
Type 2 diabetes mellitus, a metabolic disorder with man-
ifestations of hyperglycemia and hyperinsulinemia, is one
of the commonest chronic diseases worldwide [1]. Though
diﬀerent types of oral hypoglycemic agents are available
for the treatment of diabetes mellitus, there is increasing
demand by patients to use antidiabetic natural products
because of the undesirable side eﬀects of the existing drugs.
In many countries, much attention has been paid to ﬁnd
noveltypeofnaturalantidiabeticdrugsfromvariousmedici-
nalplants[2–5].Withthousandsofyearsofmedicalpractice,
a great deal of valuable experience has been accumulated in
traditional Chinese medical system for diabetic therapy and
several herbs have been used to improve the hyperglycemic
condition in diabetic patients. Because of their eﬀectiveness,
limited side eﬀects, and relatively low cost, herbal drugs
are widely prescribed even when their biologically active
compounds are unknown [6].
Mirabilis jalapa L. belongs to the family Nyctaginaceae
and is known as “four o’clock,” “maravilha,” “belle de
nuit,” “buenas tardes,” “dondiego de noche,” “jalap,” “noche
buena,” or “Tzu Mo Li” in diﬀerent areas. Mirabilis jalapa L.
is widely used to treat dysentery, diarrhea, muscular pain,
and abdominal colics in diﬀerent countries [7–9], and its
extract has antibacterial, antiviral, and antifungal functions
[10–12]. In China, Mirabilis jalapa L. is widely distributed
a n dc o m m o n l yu s e dw i t hi t sr o o ta n dh a sb e e nu s e d
as traditional Chinese medicine and ethnic drug to treat
diabetes [13, 14], constipation [15], genitourinary system
disorders, and injuries [16]. Mirabilis jalapa L. root contains
alkaloids, glycosides, carbohydrates, and phytosterols by
phytochemical analysis [9, 17]. According to literatures,
trigonelline is one of the components of Mirabilis jalapa L.
root [18]. Trigonelline has been shown to reduce blood glu-
cose concentrations in rats [19, 20] and in human [21, 22].
Only recently, Piyali et al. [17] reported the hypoglycemic2 Evidence-Based Complementary and Alternative Medicine
and hypolipidemic eﬀects of Mirabilis jalapa L. root on
streptozotocin-induced diabetic Wistar albino rats.
In this study, the experiments were designed to detect
the insulin sensitivity and hypoglycemic and hypolipidemic
activities of ethanolic extract of Mirabilis jalapa L. root
(EEM) on both diabetic and normal mice after induction
with streptozotocin with both singly and repeatedly admin-
istration, and on diabetes before induction with repeatedly
administration, and compared with glibenclamide as a
reference standard. Oral glucose tolerance test was also
measured on normal and diabetic mice after single EEM
administration.
2.MaterialsandMethods
2.1. Plant Material and EEM Preparation. The root of Mir-
abilis jalapa L. was collected from Chongqing city of China.
They were taxonomically authenticated by Dr. Guo-yue
Zhong, and a voucher specimen of the plant (TRI7374) has
been deposited in Chongqing Academy of Chinese Materia
Medica.
The root was dried in shade and powdered in a grinder.
For the preparation of EEM, dried powder of Mirabilis
jalapa L. root (2kg) was reﬂuxed with 10 volumes of 70%
ethanol three times, one hour for each time. The combined
ethanolic extract was ﬁltered using a Millipore ﬁlter (Mil-
lipore 0.2mm, St. Quentin en Yvelines, France) to remove
particulate matter. The ethanolic extract was concentrated
and dried into solid residues in vacuo (95.08mg extract/g
crude material). The residue was stored at 4◦C, and the
desired dose (g of Mirabilis jalapa L. root of per kg body
weight) was reconstituted in distilled water daily, just before
administration.
Mirabilis jalapa L. root has recently been studied for
its chemical composition by Piyali et al. [17]. The aqueous
extract had the highest (3.09%) extractive value, and the
ethyl acetate extract had the lowest (0.13%) extractive
value. The petroleum ether extract contained alkaloids, and
benzene and chloroform extracts both contained glycosides,
phytosterols; acetone extract contained alkaloids, carbohy-
drates; ethyl acetate extract contained alkaloid, carbohy-
drates, and glycoside; methanol, ethanol, and water extracts
all contained alkaloids, carbohydrates, and phytosterols.
2.2. Preliminary Phytochemical Analysis. High performance
liquid chromatography method has been developed for
the analysis of trigonelline in Mirabilis jalapa L. root
[18]. High-performance liquid chromatography analysis was
p e r f o r m e do naY W G - C 1 8c o l u m n( 2 5 0× 4.6mm, 10μm);
mobile phases: acetonitrile water (80:20, v/v); ﬂow rate:
0.8mL/min.Peakswereanalyzedspectroscopicallyat265nm
with a UV-visible-light detector. The EEM solutions were
quantiﬁed by spiking with a known amount of standard
(trigonelline) and also by comparing the area under curve.
The repeatability of the method was evaluated by injecting
the solution of EEM and standard solution for three
times, and the relative standard deviation percentage was
calculated.
2.3. Animals and Drugs. Male KM mice (18–22g) were pur-
chased from Third Military Medical University, China. The
animals were given a standard pellet diet and water ad
libitum and were maintained under standard environmental
conditions (20 ± 2◦C, 12h of light/dark cycle). Streptozo-
tocin was purchased from Sigma Co. Ltd, St. Louis, MO,
USA. Glibenclamide (no. 20100224, purity 99.56%) and
metformin hydrochloride (no. 20110809, purity 99.60%)
were purchased from Wuhan Yuancheng Technology Devel-
opment Co. Ltd, China. Insulin radioimmunoassay kit was
providedbyBeijingNorthInstituteofBiologicalTechnology,
China. All other chemicals were obtained from local sources
andwereanalyticalgrade. Throughoutthe test,experimental
mice were processed in accordance with the UK Animals
(Scientiﬁc Procedures) Act 1986 and associated guidelines.
2.4. Study of EEM on Normal Mice. Sixteen-hour-fasted nor-
m a lm i c ew e r eb o t hr a n d o m l ya s s i g n e dt oﬁ v ed i ﬀerent
groups (n = 10 in each group). The normal control group
received distilled water, and normal treated groups received
glibenclamide at a dose of 0.76mg/kg and EEM at doses of
2, 4, and 8g/kg, respectively. The selected doses of EEM were
according to the literature [13].
Single administration procedure is as follows: the
drug solutions or distilled water were administered orally
0.2mL/10g body weight by gastric intubation using a
syringe once daily at 9:00 a.m. Two hours after a single
administration, mice were anaesthetized, and the eye socket
blood of mouse was collected for measurement of blood glu-
cose level with a portable glucometer (OneTouch SureStep
Meter, LifeScan Company, USA), serum insulin, and total
cholesterol (TC) and triglyceride (TG) levels. The liver and
skeletal muscle were removed and immediately frozen in
liquid nitrogen.
The repeated administration procedure is as follows:
mice were treated as single administration once daily for
28 days. Body weights were weighed every two weeks. At
14th day, 16-hour-fasted blood sample was collected from
the tail for blood glucose measurement. At 28th day, mice
were anaesthetized and 16-hour-fasted eye socket blood of
mouse was collected for measurement of blood glucose,
serum insulin, and TC and TG levels. The liver and skeletal
muscle were also collected and frozen in liquid nitrogen.
2.5. Study of EEM on Diabetic Mice. The animals were fasted
for16hpriortotheinductionofdiabetes.Streptozotocinwas
freshly prepared in 0.1mol/L citrate buﬀer solution (pH4.5)
and was intraperitoneally injected to mice with a single dose
of 60mg/kg. After three days, 16-hour-fasted blood sample
was collected from the tail for measurement of fasting blood
glucose level. Mice with fasting blood glucose level higher
than 11.1mmol/L were considered diabetic ones and were
randomly divided into ﬁve diﬀerent groups (n = 10 in
each group). The diabetic control group received distilled
water, and diabetic treated groups received glibenclamide
at a dose of 0.76mg/kg and EEM at doses of 2, 4, and
8g/kg, respectively. The single and repeated administration
procedures were the same as in Subsection 2.4.Evidence-Based Complementary and Alternative Medicine 3
2.6. Oral Glucose Tolerance Test. Prior to an oral glucose
tolerance test, both normal and diabetic mice induced by the
above-mentioned method with fasting blood glucose level
higher than 11.1mmol/L were fasted for 16h. Distilled water
(control), two reference drugs, glibenclamide (2.5mg/kg)
and metformin (50mg/kg), and three doses of EEM (2,
4, and 8g/kg) were orally administered to groups of 10
mice each. Two hours later, glucose (2.0g/kg) was orally
administrated to each mouse. Blood samples were taken
from tail vein at 0 (just before the glucose administration),
15, 30, 60, and 120min for the assay of glucose.
2.7. Measurement of Insulin Level in Serum. Serum insulin
concentration was measured by commercial kits according
to the manufacturer’s instructions. Insulin sensitivity index
(ISI) = log (1/fasting plasma glucose × serum insulin).
2.8. Measurement of TC and TG Levels in Blood. TC and
TG levels were determined by spectrophotometry with com-
mercial kit provided by Nanjing Jiancheng Bioengineering
Institute, China.
2.9. Measurement of Glycogen and TG Contents in Liver
and Skeletal Muscle. Glycogen content was determined by
spectrophotometrywithcommercialkitprovidedbyNanjing
Jiancheng Bioengineering Institute, China. TG content in
liver and skeletal muscle was measured by the method of
Hu et al. [23]. The frozen liver (3–5mg) and skeletal muscle
(15–20mg) were used for TG extraction. Each frozen tissue
was added to 0.3mL heptane-isopropanol-tween mixture
(3:2:0.01 by volume) and homogenized. This homogenate
was centrifuged at 1500 × g at 4◦C for 15min. Supernatants
(upper phase contained extracted TG) were collected and
evaporated with vacuum centrifuge. The TG content was
determined by spectrophotometry with commercial kit
(Nanjing Jiancheng Bioengineering Institute, China).
2.10. Statistical Analyses. A l ld a t aw e r ee x p r e s s e da sm e a n±
SD. Statistical analysis was performed with one-way ANOVA
followed by Tukey post hoc test for multiple comparisons.
P<0.05 was considered signiﬁcant.
3. Results
3.1. Phytochemical Study of EEM. Phytochemical study of
EEM conﬁrmed the presence of trigonelline. The content
andvarietyoftrigonellinewhichhasamaximumabsorbance
at 256nm is 0.1818 ± 0.0109mg/g Mirabilis jalapa L. root
(Figure 1).
3.2. Eﬀects of EEM on Blood Glucose Level of Single Adminis-
tration. In streptozotocin-induced untreated diabetic mice,
fasting blood glucose level was signiﬁcantly higher than
that of untreated normal ones both before and after EEM
administration(P<0.01).Butfastingbloodglucoseleveldid
not change after single administration of EEM at doses of 2,
4, and 8g/kg either in normal or diabetic mice (Figure 2(a)).
In the diabetic mice, glibenclamide produced signiﬁcant
hypoglycemic eﬀect. But glibenclamide had no eﬀect on
glucose level of normal mice.
3.3. Eﬀects of EEM on Blood Glucose Level of Repeated Admin-
istration. Changes of blood glucose level after repeated EEM
and glibenclamide administration in normal and diabetic
mice were shown in Figure 2(b).I nn o r m a lm i c e ,b o t h
14 and 28 days of all repeated doses (2, 4, and 8g/kg)
of EEM and glibenclamide (0.76mg/kg) administration
caused no signiﬁcant reduction in blood glucose level. Both
compared to before administration and untreated diabetic
mice, reduction in blood glucose level was observed after
14 days of repeated administration of 4, 8g/kg EEM and
glibenclamide to diabetic ones (P<0.01). Progressive
reduction was observed after 28 days of repeated 4, 8g/kg
EEM administration (P<0.01). Both 14 and 28 days
of 2g/kg EEM administration resulted in no reduction in
blood glucose level. Oppositely, the blood glucose level of
untreated diabetic mice was continually increased during the
experimental period.
3.4. Eﬀects of EEM on Serum Insulin Level and ISI of Single
Administration. Signiﬁcantincreasedseruminsulinlevelbut
decreased ISI were in diabetic mice (P<0.01) when
compared to untreated normal mice. Two hours after single
administration of all doses of 2, 4, and 8g/kg EEM and
glibenclamide failed to reduce serum insulin level and to
improve ISI both in normal and diabetic mice Table 1.
3.5. Eﬀects of EEM on Serum Insulin Level and ISI of Repeated
Administration. As showed in Table 1, in normal mice, daily
administrations of 2, 4, and 8g/kg EEM and glibenclamide
over 28 days had no eﬀect on serum insulin level and
ISI. In diabetic mice, 28 days administration of 4, 8g/kg
EEM reduced serum insulin level and improved ISI when
compared to untreated diabetic mice (P<0.01). But 28-
day administration of 2g/kg EEM and glibenclamide had no
eﬀect on serum insulin level and ISI.
3.6. Eﬀects of EEM on Serum TC and TG Levels of Single
Administration. Streptozotocin injection caused signiﬁcant
increases in serum TC and TG levels (P<0.01) when
compared to untreated normal mice. Two hours after single
administration of all doses of 2, 4, and 8g/kg EEM and
glibenclamide failed to reduce serum TC and TG levels both
in normal and diabetic mice (Table 2).
3.7. Eﬀects of EEM on Serum TC and TG Levels of Repeated
Administration. Changes of serum TC and TG levels in
normal and diabetic mice during 28 days of repeated EEM
and glibenclamide administration were shown in Table 2.I n
normal mice, daily administrations of 2, 4, and 8g/kg EEM
and glibenclamide over 28 days had no eﬀect on TC and TG
levels.Indiabeticmice,28daysadministrationof2g/kgEEM
and glibenclamide did not produce any signiﬁcant change
in TC and TG levels. However, 28 days administration of 4,
8g/kg EEM reduced TC and TG levels when compared to
untreated diabetic mice (P<0.01).4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Representative high-performance liquid chromatography chromatograms of EEM and trigonelline (Rt = 19.725).
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Figure 2: Eﬀects of single and repeated EEM administration on blood glucose level in normal and diabetic mice. Data are expressed as mean
± SD, n = 10 mice per group. ∗P<0.01, compared to normal control. #P<0.01, compared to diabetic control. tP<0.01, compared to
before administration.
3.8. Eﬀects of EEM on Glycogen and TG Contents in Liver
and Skeletal Muscle of Single Administration. Changes of
glycogen and TG contents in liver and skeletal muscle of
normal and diabetic mice after single administration of
EEM and glibenclamide were shown in Table 3.I nn o r m a l
mice, single administrations of 2, 4, and 8g/kg EEM and
glibenclamide had no eﬀect on glycogen and TG contents
in liver and skeletal muscle. In diabetic mice, streptozotocin
injection caused signiﬁcant increase in TG level and decrease
in glycogen level when compared to untreated normal mice
(P<0.01).Singleadministrationof2,4,and8g/kgEEMand
glibenclamide also did not produce any signiﬁcant change
i ng l y c o g e na n dT Gc o n t e n t si nl i v e ra n ds k e l e t a lm u s c l ei n
diabetic mice.
3.9. Eﬀects of EEM on Glycogen and TG Contents in Liver
and Skeletal Muscle of Repeated Administration. Changes
o fg l y c o g e na n dT Gc o n t e n t si nl i v e ra n ds k e l e t a lm u s c l eEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀects of EEM on oral glucose tolerance test in normal and diabetic mice. Data are expressed as mean ± SD, n = 10 mice per
group. ∗P<0.01, compared to normal control. #P<0.01, compared to diabetic control.
Table 1: Eﬀects of single and repeated EEM administration on serum insulin level and ISI in normal and diabetic mice.
Group
Single administration Repeated administration
Serum insulin (mU/L) ISI Serum insulin (mU/L) ISI
Normal control 11.80 ±0.83 −1.88 ±0.06 11.49 ±1.17 −1.85 ±0.04
Normal + 2g/kg EEM 11.65 ±0.44 −1.88 ±0.04 11.68 ±0.60 −1.87 ±0.04
Normal + 4g/kg EEM 11.60 ±0.79 −1.86 ±0.06 11.55 ±0.63 −1.86 ±0.05
Normal + 8g/kg EEM 11.06 ±0.30 −1.86 ±0.05 11.67 ±0.64 −1.86 ±0.05
Normal + glibenclamide 11.91 ±0.36 −1.89 ±0.04 11.54 ±0.75 −1.85 ±0.06
Diabetic control 16.74 ±0.53∗ −2.45 ±0.05∗ 14.81 ± 1.04∗ −2.48 ±0.05∗
Diabetic + 2g/kg EEM 16.43 ±0.43 −2.44 ±0.05 14.65 ±1.88 −2.48 ±0.08
Diabetic + 4g/kg EEM 16.01 ±0.53 −2.43 ±0.03 11.88 ±0.90 −2.04 ±0.08#
Diabetic + 8g/kg EEM 16.07 ±0.95 −2.42 ±0.04 11.68 ±0.81 −2.03 ±0.05#
Diabetic + glibenclamide 36.83 ±4.82# −2.40 ±0.09 39.15 ±6.55# −2.42 ±0.09
Insulin sensitivity index (ISI) = log (1/fasting plasma glucose × serum insulin). Data are expressed as mean ± SD, n = 10 mice per group. ∗P<0.01 when
compared to normal control. #P<0.01 when compared to diabetic control.
Table 2: Eﬀects of single and repeated EEM administration on serum TC and TG levels in normal and diabetic mice.
Group
Single administration Repeated administration
TC (mmol/L) TG (mmol/L) TC (mmol/L) TG (mmol/L)
Normal control 2.13 ±0.20 0.74 ±0.07 2.13 ±0.16 0.75 ±0.06
Normal + 2g/kg EEM 2.11 ±0.20 0.75 ±0.11 2.14 ±0.17 0.75 ±0.06
Normal + 4g/kg EEM 2.17 ±0.22 0.77 ±0.09 2.14 ±0.20 0.74 ±0.05
Normal + 8g/kg EEM 2.08 ±0.22 0.75 ±0.08 2.10 ±0.16 0.73 ±0.06
Normal + glibenclamide 2.11 ±0.21 0.75 ±0.08 2.11 ±0.14 0.74 ±0.08
Diabetic control 3.47 ±0.33∗ 1.26 ±0.12∗ 3.49 ±0.32∗ 1.28 ±0.09∗
Diabetic + 2g/kg EEM 3.45 ±0.39 1.24 ±0.10 3.47 ±0.26 1.24 ±0.11
Diabetic + 4g/kg EEM 3.44 ±0.43 1.24 ±0.12 2.92 ±0.22# 1.01 ±0.11#
Diabetic + 8g/kg EEM 3.44 ±0.31 1.25 ±0.10 2.82 ±0.25# 0.97 ±0.07#
Diabetic + glibenclamide 3.48 ±0.34 1.23 ±0.10 3.46 ±0.13 1.27 ±0.09
Data are expressed as mean ± SD, n = 10 mice per group. ∗P<0.01 when compared to normal control. #P<0.01 when compared to diabetic control.6 Evidence-Based Complementary and Alternative Medicine
Table 3: Eﬀects of single EEM administration on glycogen and TG contents in liver and skeletal muscle of normal and diabetic mice.
Group
Liver Skeletal muscle
Glycogen (mg/g) TG (μmol/g) Glycogen (mg/g) TG (μmol/g)
Normal control 12.73 ±0.89 3.40 ±0.22 1.69 ±0.16 0.116 ±0.005
Normal + 2g/kg EEM 12.58 ±0.91 3.40 ±0.20 1.67 ±0.12 0.115 ±0.005
Normal + 4g/kg EEM 12.46 ±0.74 3.47 ±0.29 1.65 ±0.06 0.117 ±0.006
Normal + 8g/kg EEM 12.57 ±0.96 3.44 ±0.31 1.69 ±0.12 0.115 ±0.007
Normal + glibenclamide 12.66 ±0.96 3.40 ±0.35 1.68 ±0.15 0.111 ±0.010
Diabetic control 6.77 ±0.55∗ 5.17 ±0.26∗ 2.89 ±0.20∗ 0.215 ±0.017∗
Diabetic + 2g/kg EEM 6.99 ±0.60 5.27 ±0.48 2.89 ±0.21 0.213 ±0.016
Diabetic + 4g/kg EEM 7.04 ±0.55 5.35 ±0.39 2.72 ±0.21 0.219 ±0.013
Diabetic + 8g/kg EEM 7.20 ±0.35 5.28 ±0.40 2.73 ±0.36 0.201 ±0.014
Diabetic + glibenclamide 7.18 ±0.56 5.25 ±0.35 2.76 ±0.28 0.199 ±0.013
Data are expressed as mean ± SD, n = 10 mice per group. ∗P<0.01 when compared to normal control.
Table 4: Eﬀects of repeated EEM administration on glycogen and TG contents in liver and skeletal muscle of normal and diabetic mice.
Group
Liver Skeletal muscle
Glycogen (mg/g) TG (μmol/g) Glycogen (mg/g) TG (μmol/g)
Normal control 12.43 ±1.19 3.39 ±0.28 1.66 ±0.16 0.126 ±0.009
Normal + 2g/kg EEM 12.36 ±1.05 3.45 ±0.16 1.55 ±0.14 0.123 ±0.007
Normal + 4g/kg EEM 12.67 ±1.00 3.50 ±0.25 1.72 ±0.17 0.131 ±0.011
Normal + 8g/kg EEM 12.75 ±1.33 3.35 ±0.27 1.70 ±0.15 0.131 ±0.008
Normal + glibenclamide 12.81 ±1.06 3.28 ±0.26 1.71 ±0.12 0.128 ±0.007
Diabetic control 6.86 ±0.41∗ 5.28 ±0.21∗ 2.75 ±0.20∗ 0.226 ±0.016∗
Diabetic + 2g/kg EEM 7.28 ±0.36 5.29 ±0.34 2.75 ±0.28 0.215 ±0.019
Diabetic + 4g/kg EEM 9.38 ±1.14# 4.24 ± 0.37# 2.04 ±0.22# 0.170 ±0.008#
Diabetic + 8g/kg EEM 9.79 ±0.99# 4.09 ± 0.30# 2.03 ±0.17# 0.164 ±0.011#
Diabetic + glibenclamide 10.81 ±0.77# 5.15 ±0.33 1.79 ±0.13# 0.221 ±0.020
Data are expressed as mean ± SD, n = 10 mice per group. ∗P<0.01 when compared to normal control. #P<0.01 when compared to diabetic control.
of normal and diabetic mice during 28 days of EEM and
glibenclamide administration were shown in Table 4.I n
normal mice, once daily administrations of 2, 4, and 8g/kg
EEMandglibenclamidefor28dayshadnoeﬀectonglycogen
and TG contents in liver and skeletal muscle. In diabetic
mice, glycogen content was signiﬁcantly lower, and TG
content was signiﬁcantly higher than those of untreated
normalmice(P<0.01).Administrationof2g/kgEEMfor28
days did not produce any signiﬁcant change in glycogen and
TG contents in liver and skeletal muscle. However, repeated
administration of 4, 8g/kg EEM signiﬁcantly increased
glycogen content and reduced TG content in liver and
skeletal muscle compared with untreated diabetic mice (P<
0.01).Repeatedadministrationofglibenclamidesigniﬁcantly
increased glycogen content (P<0.01), but did not aﬀect TG
content in liver and skeletal muscle compared with untreated
diabetic mice.
3.10. Eﬀects of EEM on the Oral Glucose Tolerance Test. In
normal mice, EEM (4, 8g/kg) signiﬁcantly inhibited the
increase in blood glucose level after glucose load (P<0.01)
(Figure 3(a)), while low dose of EEM (2g/kg) showed no
inhibitory eﬀect. In comparative groups, both glibenclamide
(2.5mg/kg) and metformin (50mg/kg) signiﬁcantly inhib-
ited the increase in glucose level (P<0.01). In the diabetic
mice, EEM (4, 8g/kg) also showed signiﬁcantly inhibitory
eﬀect on the increased blood glucose level after glucose load
(P<0.01) (Figure 3(b)), while low dose of EEM (2g/kg) did
not inhibit the increase in blood glucose level. The inhibitory
activities of glibenclamide and metformin were observed
after oral glucose load (P<0.01).
When 2, 4, and 8g/kg EEM and glibenclamide were
administered for two weeks before induction of diabetes
with streptozotocin and for a further 28 days afterwards,
essentially similar eﬀects were observed on blood glucose,
serum insulin, ISI, serum TC, serum TG, glycogen, and TG
contents in liver and skeletal muscle to those seen when
EEM and glibenclamide were administered after induction
of diabetes (data not shown).
4. Discussion
Blood glucose level was increased signiﬁcantly from the 3rd
day in untreated diabetic mice. This increment may be due
to reduced glucose clearance apparently arising from a defect
in glucose transport [24] and/or to the early appearance inEvidence-Based Complementary and Alternative Medicine 7
insulin resistance in diabetic mice [25]. The experimental
diabetic mice used in this study were type 2 diabetic ones
because low dose of streptozotocin (60mg/kg) destroyed half
a population of pancreatic β cells and had a high blood
glucose level, which are in accord with the results of previous
investigations [26, 27]. Single administration EEM had no
eﬀect on blood glucose, TC, TG levels and glycogen, and
TG contents in liver and skeletal muscle of both normal and
diabetic mice. What is more, repeated administration EEM
did not aﬀect blood glucose, TC, TG levels and glycogen,
a n dT Gc o n t e n t si nl i v e ra n ds k e l e t a lm u s c l eo fn o r m a lm i c e .
These results suggest that EEM had no hypoglycemic and
hypolipidemic eﬀects on normal mice.
When studying a chronic disease such as diabetes, it is
more pertinent to test the maintenance of lower blood glu-
cose level with long-term treatment rather than the acute
hypoglycemic eﬀect after a single administration. In this
study, we found that repeated administration EEM contin-
ually decreased blood glucose level in diabetic mice both
after and before induction with streptozotocin. In diabetic
liver and skeletal muscle, glycogen content was lower and
TG content was higher than those of normal mice, which
accords with other reports [28], and this phenomenon
was related with impaired glucose synthesis in the mouse
liver and skeletal muscle during diabetes [29]. Repeated
EEM administration signiﬁcantly increased tissue glycogen
content in diabetic mice. In the oral glucose tolerance test,
EEM (4, 8g/kg) signiﬁcantly improved hyperglycemia after
oral glucose load both in normal and diabetic mice. On the
other hand, the higher dose of glibenclamide (2.5mg/kg),
one of the sulfonylureas that stimulates insulin secretion
[30], and metformin, one of the iguanids that inhibits
hepatic glucose output [31], improved hyperglycemia after
oralglucoseload.TwohoursaftersingleEEMadministration
failed to reduce serum insulin level and to improve ISI both
in normal and diabetic mice. Repeated EEM administration
to diabetic mice decreased serum insulin level and improved
ISI, but not for normal mice. The prevention of depletion of
glycogen in the liver and skeletal muscle by EEM may be due
to improved ISI, but not for stimulation of insulin release
from β cells.
Several medicinal plants have been reported to restore
activity of key enzymes of glucose and glycogen metabolism
which are strongly disturbed in streptozotocin-induced
diabetic mice [32, 33]. Hypoglycemic activity of EEM may
arise from inhibition of hepatic glucose production. Several
medicinal plants possess an insulin-sensitizing activity in
experimental diabetic mice [34, 35]. Since streptozotocin-
induced diabetes is accompanied by insulin resistance, EEM
improvedinsulinsensitivity.Itwasreportedthatatraditional
herbal medicine improved insulin action in streptozotocin-
induced diabetic mice via enhancing insulin signaling [36,
37]. So other underlying mechanisms of the blood glucose
lowering activity of EEM need further study.
The philosophy behind the medicinal uses of traditional
Chinese medicine is holistic in nature, which diﬀers from
western medicines, and all chemical components present in
a particular traditional Chinese medicine are believed to be
of therapeutic importance. It was generally recommended
to separate and measure the active chemical ingredients for
standardizationandqualitycontrolofherbalproducts.What
is more, the conﬁrmation of main constituent in herb and
herbal extract helps to clarify its pharmacological eﬀects.
Previous studies reported that the Mirabilis jalapa L. root
contains phytocompounds, such as alkaloids, glycosides, car-
bohydrates, and phytosterols [9, 17]. Phytochemical analysis
shows that the Mirabilis jalapa L. roots contain plentiful
trigonelline. As one of the components of Mirabilis jalapa L.
root, trigonelline reduced blood glucose level in animal and
human [19–22] and improved glucose tolerance in diabetes
with obesity by oral glucose tolerance test. Trigonelline
also reduced TC, free plasma cholesterol, and TG levels
in the serum, liver, and adipose tissue [38, 39]. What is
more, trigonelline decreased serum insulin, serum tumor
necrosis factor α levels, and liver fatty acid synthase activity
and increased carnitine palmitoyl transferase, glucokinase
activities, and glucokinase/glucose-6-phosphatase ratio in
the liver [38, 40]. Therefore, it was reasonable to suggest
that the insulin sensitivity, hypoglycemia, and hypolipidemia
proﬁle of EEM might be connected to the existence of
thephytocompounds,especiallythetrigonelline.Meanwhile,
our results clearly demonstrate that administration EEM
provides beneﬁcial insulin sensitivity, hypoglycemic, and
hypolipidemic eﬀects especially on diabetic mice both after
and before induction with streptozotocin.
In conclusion, our study demonstrates that Mirabilis
jalapa L. root can be used to treat type 2 diabetes with
hyperlipidemia. Mirabilis jalapa L. root may be developed as
an oral hypoglycemic agent or functional food for diabetic
patients with hyperlipidemia and for persons with high
risk of diabetes. This ﬁnding represents an experimen-
tal conﬁrmation of the Chinese traditional use of this
plant for diabetic treatment. Consequently, consumption of
Mirabilis jalapa L. root may prevent the complication of
hyperglycemia associated with diabetes. Finally, the precise
mechanism(s) and site(s) of this activity and the active
constituent(s) of Mirabilis jalapa L. root still need to be
determined in addition to toxicological studies in further
experiments.
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